Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: sarcoplasmic reticulum calcium transporting ATPase stimulants - Windtree Therapeutics

Next Previous
Drug Profile

Research programme: sarcoplasmic reticulum calcium transporting ATPase stimulants - Windtree Therapeutics

Alternative Names: SERCA2a activators - Windtree Therapeutics

Latest Information Update: 07 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CVie Therapeutics
  • Developer Windtree Therapeutics
  • Class Heart failure therapies
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute heart failure; Chronic heart failure

Most Recent Events

  • 16 Apr 2024 Windtree Therapeutics has patent protection for SERCA2a activators in Europe, USA, China, Hong Kong, and Japan as of April 2024
  • 16 Apr 2024 Windtree Therapeutics has patents pending for SERCA2a stimulators for the treatment of heart failure and related conditions in Australia, Brazil, Canada, China, Hong Kong, Israel, Japan, Mexico, Republic of Korea, Singapore, and USA as of April 2024
  • 01 Feb 2024 Windtree renews agreement with Chang Gung University for SERCA2a research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top